Medicare Enrolled
Dr. Celeste Wilcox, MD, PHD
Medical Oncology · Paris, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Wilcox from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Wilcox? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Wilcox
Dr. Celeste Wilcox is a medical oncology in Paris, TX, with 19 years in practice. Based on federal Medicare data, Dr. Wilcox performed 207,951 Medicare services across 5,230 unique beneficiaries.
Between the years covered by Open Payments, Dr. Wilcox received a total of $597 from 13 pharmaceutical and/or device companies across 15 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Wilcox is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 2% volume in TX$ $597 industry payments
Medicare Practice Summary
Medicare Utilization ↗207,951
Medicare services
Top 2% in TX for medical oncology
5,230
Unique beneficiaries
$8
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~10,945 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 66,300 | $0 | $5 |
| Anti-nausea injection (fosaprepitant) | 23,700 | $0 | $5 |
| Darbepoetin injection (Aranesp) for anemia | 21,159 | $2 | $20 |
| Pembrolizumab injection (Keytruda) | 18,800 | $42 | $137 |
| Oxaliplatin chemotherapy injection | 14,750 | $0 | $33 |
| Contrast dye for imaging (iodine-based) | 12,084 | $0 | $3 |
| Paclitaxel chemotherapy injection | 10,711 | $0 | $8 |
| Immune globulin infusion (Octagam) | 6,510 | $34 | $233 |
| Dexamethasone injection (steroid) | 5,188 | $0 | $1 |
| Denosumab injection (Prolia/Xgeva) | 3,960 | $18 | $66 |
| Injection, docetaxel, 1 mg | 3,026 | $0 | $66 |
| Anti-nausea injection (Aloxi/palonosetron) | 2,520 | $1 | $114 |
| Injection, granisetron hydrochloride, 100 mcg | 1,490 | $0 | $24 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 1,400 | $23 | $155 |
| Epoetin alfa injection (Retacrit) for anemia | 1,275 | $6 | $28 |
| Complete blood count (CBC) with differential | 1,200 | $8 | $36 |
| Blood draw (venipuncture) | 1,143 | $8 | $20 |
| Comprehensive metabolic blood panel | 939 | $10 | $64 |
| Injection of additional new drug or substance into vein | 812 | $12 | $108 |
| Lactate dehydrogenase (enzyme) level | 733 | $6 | $31 |
| Injection, leucovorin calcium, per 50 mg | 687 | $3 | $25 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 606 | $22 | $157 |
| Administration of chemotherapy into vein, 1 hour or less | 576 | $97 | $707 |
| Injection, carboplatin, 50 mg | 555 | $2 | $300 |
| Office visit, established patient (30-39 min) | 549 | $90 | $368 |
| Injection, fluorouracil, 500 mg | 494 | $2 | $13 |
| Office visit, established patient (20-29 min) | 444 | $61 | $250 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 393 | $3 | $373 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 378 | $47 | $313 |
| Injection, zoledronic acid, 1 mg | 348 | $7 | $431 |
| Drug injection, under skin or into muscle | 329 | $10 | $96 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 300 | $70 | $1,348 |
| Injection, diphenhydramine hcl, up to 50 mg | 259 | $1 | $7 |
| Injection, potassium chloride, per 2 meq | 230 | $0 | $1 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 228 | $272 | $2,762 |
| Ferritin level test (iron stores) | 213 | $13 | $60 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 207 | $15 | $100 |
| Iron level test | 201 | $6 | $27 |
| Iron binding capacity test | 201 | $8 | $35 |
| Administration of additional new drug or substance into vein, 1 hour or less | 200 | $47 | $344 |
| Cyclophosphamide, 100 mg | 190 | $16 | $203 |
| Reticulated (young) platelet measurement | 159 | $35 | $143 |
| Microscopic examination for white blood cells with manual cell count | 158 | $4 | $22 |
| Complete blood count (CBC), automated | 158 | $6 | $34 |
| Infusion, normal saline solution , 1000 cc | 149 | $2 | $19 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 144 | $55 | $211 |
| Administration of chemotherapy into vein, each additional hour | 134 | $21 | $161 |
| Ct scan of chest with contrast | 122 | $53 | $821 |
| Injection, magnesium sulfate, per 500 mg | 120 | $1 | $6 |
| Irrigation of implanted venous access drug delivery device | 108 | $17 | $114 |
| Unclassified drugs | 105 | $1 | $8 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 103 | $26 | $145 |
| Infusion into a vein for hydration, each additional hour | 102 | $10 | $75 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 89 | $74 | $70 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 80 | $136 | $3,675 |
| CT scan of abdomen and pelvis with contrast | 79 | $171 | $1,067 |
| Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev | 73 | $178 | $700 |
| Hospital follow-up visit, moderate complexity | 62 | $60 | $247 |
| Blood creatinine level | 58 | $5 | $31 |
| Administration of additional new drug or substance into vein using push technique | 58 | $42 | $289 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 56 | $15 | $94 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 52 | $124 | $500 |
| CT scan of chest, without contrast | 48 | $41 | $686 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 37 | $90 | $657 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 35 | $1,109 | $4,802 |
| Office visit, established patient (10-19 min) | 35 | $36 | $150 |
| Red blood count, automated test | 34 | $4 | $23 |
| Ct scan of abdomen and pelvis without contrast | 32 | $76 | $560 |
| Basic metabolic blood panel | 30 | $8 | $49 |
| New patient office visit (45-59 min) | 29 | $109 | $565 |
| PSA test (prostate cancer screening) | 26 | $18 | $94 |
| Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 mev | 26 | $177 | $700 |
| Ct scan of abdomen with contrast | 23 | $134 | $793 |
| Hospital follow-up visit, low complexity | 22 | $38 | $135 |
| Application of on-body injector for under skin injection | 21 | $14 | $96 |
| Office visit, established patient, complex (40-54 min) | 20 | $130 | $496 |
| Hospital follow-up visit, high complexity | 18 | $91 | $357 |
| Infusion into a vein for hydration, 31-60 minutes | 16 | $25 | $256 |
| New patient office visit, complex (60-74 min) | 16 | $168 | $709 |
| Flu vaccine, quadrivalent | 13 | $76 | $171 |
| Flu vaccine administration | 13 | $30 | $58 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
35.8% high complexity
60.6% medium
3.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$597
Total received (2018-2024)
Avg $85/year across 7 years
Bottom 24% in TX for medical oncology
13
Companies
15
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$530 (88.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$66 (11.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$68
2023$50
2022$25
2021$182
2020$40
2019$125
2018$106
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Myriad Genetic Laboratories, Inc.
$132
Astellas Pharma US Inc
$125
Medtronic USA, Inc.
$106
E.R. Squibb & Sons, L.L.C.
$76
Pharmacyclics LLC, an AbbVie Company
$25
Myovant Sciences Inc.
$24
ABBVIE INC.
$19
Daiichi Sankyo Inc.
$18
Takeda Pharmaceuticals U.S.A., Inc.
$16
Pharmacyclics LLC, An AbbVie Company
$15
Novartis Pharmaceuticals Corporation
$14
Acrotech Biopharma LLC
$14
Gilead Sciences, Inc.
$12
Top 3 companies account for 60.9% of total payments
Associated products mentioned in payments ›
BELEODAQ · EPKINLY · Enhertu · FRUZAQLA · IMBRUVICA · KISQALI · OPDIVO · ORGOVYX · OSTEOCOOL RF ABLATION · XOSPATA · myChoice CDx
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (89%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $0 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
3
Per 100K population
5.9
County median income
$61,122
Nearest hospital
PARIS REGIONAL MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Wilcox is a mixed practice specialist, with above-average Medicare volume (top 2% in TX), and low-engagement industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Wilcox experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Wilcox performed 66,300 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Wilcox receive payments from pharmaceutical companies?
Yes. Dr. Wilcox received a total of $597 from 13 companies across 15 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Wilcox's costs compare to other medical oncologys in Paris?
Dr. Wilcox's average Medicare payment per service is $8. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Wilcox) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Paris
Browse medical oncologys in Paris ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in TX
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in TX
Which TX medical oncologys receive the most from drug and device companies.
By company
Myriad Genetic Laboratories, Inc. Payments to Doctors
See all physicians who received payments from Myriad Genetic Laboratories, Inc..
By company
Astellas Pharma US Inc Payments to Doctors
See all physicians who received payments from Astellas Pharma US Inc.
By company
Medtronic USA, Inc. Payments to Doctors
See all physicians who received payments from Medtronic USA, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology